SCHEMBL458500

SCHEMBL458500

NNC(=S)NC1CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 1.00
LMNA P02545 1/20 1.00
ALDH1A1 P00352 2/20 0.73
CYP3A4 P08684 2/20 0.73
TP53 P04637 1/20 0.73
SMN1; SMN2 Q16637 5/20 0.65
NPC1 O15118 4/20 0.48
RAB9A P51151 3/20 0.48
MAPK1 P28482 1/20 0.48
DUSP3 P51452 1/20 0.48
PTPN5 P54829 1/20 0.48
PTPN11 Q06124 1/20 0.48
PKM P14618 1/20 0.47
HTT P42858 1/20 0.47
EPHX1 P07099 5/20 0.46
MAPT P10636 1/20 0.46
KDM4E B2RXH2 1/20 0.46
EPHX2 P34913 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10488946 1.00 GAA (1.00) GAALMNAALDH1A1CYP3A4TP53
SCHEMBL10488607 1.00 GAA (1.00) GAALMNAALDH1A1CYP3A4TP53
SCHEMBL1991458 0.98 GAA (0.95) GAALMNAALDH1A1CYP3A4TP53
SCHEMBL5098857 0.87
Hydrochloric Acid SCHEMBL27472901 0.85
SCHEMBL491492 0.85 ALDH1A1 (1.00) GAALMNAALDH1A1CYP3A4TP53
SCHEMBL11597254 0.85 ALDH1A1 (1.00) GAALMNAALDH1A1CYP3A4TP53
SCHEMBL11842060 0.85 ALDH1A1 (1.00) GAALMNAALDH1A1CYP3A4TP53
SCHEMBL21560406 0.80 ALDH1A1 (0.80) GAALMNAALDH1A1CYP3A4TP53
SCHEMBL3075189 0.79 ALDH1A1 (0.70) GAALMNAALDH1A1CYP3A4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016111658-A1 SYNTHESIS OF THIOSEMICARBAZONE DERIVATIVES COMPRISING SULPHONAMIDE GROUP WITH POTENTIAL ANTICONVULSANT ACTIVITY IYIDOGAN AYSEGUL (TR) 2016-07-14 WO claimed
EP-2827864-B1 INHIBITION OF MCL-1 AND/OR BFL-1/A1 DANA FARBER CANCER INST INC (US) 2020-09-30 EP disclosed
EP-2827864-B1 INHIBITION OF MCL-1 AND/OR BFL-1/A1 DANA FARBER CANCER INST INC (US) 2020-09-30 EP disclosed
US-9926306-B2 Inhibition of MCL-1 and/or BFL-1/A1 DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-03-27 US disclosed
US-9926306-B2 Inhibition of MCL-1 and/or BFL-1/A1 DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-03-27 US disclosed
WO-2016111658-A1 SYNTHESIS OF THIOSEMICARBAZONE DERIVATIVES COMPRISING SULPHONAMIDE GROUP WITH POTENTIAL ANTICONVULSANT ACTIVITY IYIDOGAN AYSEGUL (TR) 2016-07-14 WO disclosed
US-20150051249-A1 INHIBITION OF MCL-1 AND/OR BFL-1/A1 NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-19 US disclosed
US-20150051249-A1 INHIBITION OF MCL-1 AND/OR BFL-1/A1 NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-19 US disclosed
EP-2827864-A1 INHIBITION OF MCL-1 AND/OR BFL-1/A1 Dana-Farber Cancer Institute, Inc. (US) 2015-01-28 EP disclosed
CN-102532126-B 2-substituted-4-chloro-5-[5-subtsituted amino-2-(1,3,4-thiadiazole)-sulfydryl]-3(2H)- pyridazinone derivatives, and preparation method and application thereof UNIV GUIZHOU 2014-06-18 CN disclosed
WO-2002098420-A1 4-SUBSTITUTED-1-(ARYLMETHYLIDENE)THIOSEMICARBAZIDE, 4-SUBSTITUTED-1-(ARYLCARBONYL)THIOSEMICARBAZIDE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2002-12-12 WO disclosed
US-4871737-A 3-Amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants muscle relaxants and anxiolytics A. H. ROBINS COMPANY, INCORPORATED (US) 1989-10-03 US disclosed
EP-0315433-A2 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics A.H. ROBINS COMPANY, INCORPORATED (US) 1989-05-10 EP disclosed
US-4826866-A 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics A. H. ROBINS COMPANY, INCORPORATED (US) 1989-05-02 US disclosed
US-4492793-A Process for the production of 2-amino-5-mercapto-1,3,4-thiadiazole DEGUSSA AKTIENGESELLSCHAFT (DE) 1985-01-08 US disclosed
US-4271308-A FUNGICIDES ROHM AND HAAS COMPANY (US) 1981-06-02 US disclosed
US-4120864-A FUNGICIDES ROHM AND HAAS COMPANY (US) 1978-10-17 US disclosed
US-4069377-A Polymerization of ethylenically unsaturated monomers employing secondary-aliphatic α-substituted azoalkanes PENNWALT CORPORATION 1978-01-17 US disclosed
US-4028344-A FOAMING AGENTS, FREE RADICAL INITIATORS PENNWALT CORPORATION (US) 1977-06-07 US disclosed
US-4025502-A POLYMERIZATION CATALYSTS, CURING AGENTS PENNWALT CORPORATION (US) 1977-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051249-A1 INHIBITION OF MCL-1 AND/OR BFL-1/A1 BCL2L1, MCL1, BCL2A1 GAA 1744/4885LMNA 319/4885ALDH1A1 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.